Want to Beat the TSX? Buy These 3 Stocks Poised for Monster Long-Term Growth

A sluggish Canadian stock market should drive investors to the health industry and stocks like Jamieson Wellness Inc. (TSX:JWEL).

| More on:
The Motley Fool

The S&P/TSX Index slipped 16 points on April 4. The index is now down 6.4% in 2018. A slew of less-than-stellar economic news also served to increase anxiety among investors. Statistics Canada reported that GDP inched down 0.1% in the month of January, and home sales and prices have been in a dramatic year-over-year slide.

In addition, the blockchain and cannabis mania has come to a screeching halt. This leaves investors on the hunt for growth in a precarious position. Where should they turn? Today we’re going to look at three stocks in the intriguing health sector that should pique the interest of those looking for the possibility of explosive long-term gains.

Zymeworks Inc.

Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) is a biopharmaceutical company in the clinical stage; the company is focused primarily on cancer treatment. Zymeworks stock rose 3.29% on April 4, surging 50% in 2018 thus far. In its most recent fourth-quarter report, the company announced that ZW49 would be the first product candidate selected for clinical development using the Zymelink platform acquired in 2016.

Its leading product, ZW25, is in phase 1 of clinical trials for breast cancer. Raymond James analysis projected that ZW25 has the potential to compete with Herceptin and Perjeta in the U.S., which brought in billions in revenue in 2017. Zymeworks stock is down 19.8% year over year and could still be a bargain given its long-term promise.

Jamieson Wellness Inc.

Jamieson Wellness Inc. (TSX:JWEL) is a Toronto-based company that specializes in sports nutrition and specialty supplements. Jamieson stock has climbed 2.9% in 2018 as of close on April 4. The company reported a net loss in 2017, but is inching close to profitability for the first time since its public listing. Jamieson showed promise in 2017 as revenue jumped 21.1% to $300.6 million and adjusted EBITDA climbed 31.4% to $61.5 million. Jamieson also offers a solid quarterly dividend of $0.08 per share, thereby representing a 1% dividend yield.

Jamieson projects 2018 revenue to hit between $325 million and $335 million and adjusted diluted earnings per share to reach $0.83 to $0.87. The supplements market is expected to be buoyed by an aging population in the West and its high disposable wealth in the coming decades. According to Grand View Research Inc., the global dietary supplements market is expected to reach $278.4 billion by 2024, representing a compound annual growth rate (CAGR) of about 9.5%.

Cardiome Pharma Corp.

Cardiome Pharma Corp. (TSX:COM)(NASDAQ:COM) is a Vancouver-based specialty pharmaceutical company. Shares of Cardiome rose 4.58% on April 4 and have climbed 48.6% in 2018 so far. However, the stock has plunged 29% year over year.

Selling, general and administrative expenses rose to $10.4 million in the fourth quarter due to an expansion of its workforce in Europe and the launch of Xydalba, which treats Acute Bacterial Skin and Skin Structure Infections, and Zevtera/Mabelio, an antibiotic for the treatment of community and hospital acquired pneumonia. The launch of Xydalba and the recognition of sales revenue from the latter has the potential to return positive cash flow to Cardiome in 2018. It is an attractive speculative buy in April.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ambrose O'Callaghan has no position in any of the stocks mentioned.

More on Investing

Silver coins fall into a piggy bank.
Tech Stocks

How to Turn a $500 TFSA or RRSP Into $50,000

Are you looking to convert a $500 TFSA into $50,000? A little discipline and patience can help you achieve it.…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

5 Things to Know About Cannabis Stocks Before 2023

Cannabis stocks like Canopy Growth (TSX:WEED) are struggling, but there are positives to draw on as well.

Read more »

Stocks for Beginners

3 Best-in-Class Stocks to Build Long-Term Wealth

Looking for stocks that might create generational wealth over the long term? Here's a top growth, value, and income stock…

Read more »

TFSA and coins
Dividend Stocks

TFSA Couples: How to Invest for $777 of Passive Income Each Month

The TFSA or Tax-Free Savings Account can be used to buy and hold a portfolio of blue chip dividend stocks…

Read more »

A close up image of Canadian $20 Dollar bills
Dividend Stocks

Investing in the Stock Market Could Turn Your $1,000 Into $100,000: Here’s How

The stock market can convert a $1,000 regular investment into $100,000 without making too risky bets. Here’s a simple strategy…

Read more »

Bank Stocks

3 Top Stocks to Buy Now in a Once-in-a-Decade Opportunity

Given their discounted stock prices, these three quality stocks offer a once-in-a-decade buying opportunity.

Read more »

Various Canadian dollars in gray pants pocket
Stocks for Beginners

Here’s an Absolutely Brilliant Way to Earn Passive Income

Here’s a simple and unique way to earn passive income that does not involve working more, buying a property, or…

Read more »

Make a choice, path to success, sign
Stocks for Beginners

Canadian Investors: 2 Once-in-a-Generation Buying Opportunities

You can grab these two once-in-a-generation buying opportunities in Canada right now to get super rich in the long term.

Read more »